Boston Scientific Corporation vs Snap On Incorporated — how do they compare? Boston Scientific Corporation trades at $51.73 (market cap $74.19B), while Snap On Incorporated trades at $409.67 (market cap $21.30B). The key difference: Boston Scientific Corporation is far larger — about 3.5× Snap On Incorporated's market cap, and Snap On Incorporated pays a 2.37% dividend while Boston Scientific Corporation pays none. Which is the better fit depends on your goals.
| BSX | SNA | |
|---|---|---|
Market Cap | $74.19B | $21.30B |
Sector | Health | Technology |
52-Week High | $108.14 | $419.31 |
52-Week Low | $42.63 | $321.38 |
Enterprise Value | $86.27B | $20.93B |
Dividend Yield | — | 2.37% |
Signals from Pluang's Aura AI — not financial advice
Boston Scientific (BSX) trades at $51.66, up 2.38% today, showing strong momentum with three consecutive quarterly earnings beats. The stock maintains bullish technical signals with moving averages supporting upward movement, though oscillators indicate potential overbought conditions. Fundamentally, BSX demonstrates robust growth with 2025 revenue reaching $20.07B and net income margin expanding to 14.43%, supported by strong cash flow generation of $1.54B in 2025.
The outlook remains positive with 86% analyst buy ratings and a $67.21 consensus price target offering 30% upside potential. Key risks include competitive pressures in WATCHMAN and electrophysiology segments, along with recent guidance cuts. Insider buying by the CEO and director signals management confidence in the company's long-term prospects despite near-term challenges.
Snap-on Incorporated (SNA) trades at $407.78, down 0.81% on the day, with a bullish technical outlook supported by moving averages. The company maintains strong fundamentals with 19.6% net income margin and 17.58% ROE, though valuation metrics appear elevated at P/E 21.01 and P/S 4.12. Recent Q2 2026 earnings beat expectations with $4.96 EPS, while the $100 million Diesel Laptops acquisition expands diagnostic capabilities.
SNA offers growth potential through strategic acquisitions and operational efficiency, with analyst consensus target of $455.33 suggesting 11.7% upside. Key risks include integration challenges from recent acquisitions and premium valuation pressure. The bullish technical setup combined with strong profitability supports a positive medium-term outlook despite near-term valuation concerns.
Trailing returns across standard periods
Latest headlines on both assets
Boston Scientific produces less invasive medical devices that are inserted into the human body through small openings or cuts. It manufactures products for use in angioplasty, blood clot filtration, cardiac rhythm management, catheter-directed ultrasound imaging, structural heart disease, upper gastrointestinal tract diagnostics, interventional oncology, and treatment of incontinence. The firm markets its devices to healthcare professionals and institutions globally. Foreign sales account for nearly half of the firm's total sales.
Read more on BSX →Snap-on Incorporated is a leading global innovator, manufacturer, and marketer of tools, equipment, diagnostics, repair information, and systems solutions for professional users. Its products are widely used in vehicle service and repair, as well as in other demanding industrial environments. The company is best known for its premium tool brand, often sold through a network of franchised mobile stores, and is a primary supplier to technicians in the transportation industry.
Read more on SNA →